Stephanie Herron was named chief development officer of Stand Up To Cancer. In this newly created position, she will be responsible for the growth and development of SU2C’s fundraising strategy, focusing on major gifts, corporate philanthropy, digital engagement, and innovation.
Pedro Torres-Ayuso was named assistant professor in the Department of Cancer and Cellular Biology at the Lewis Katz School of Medicine at Temple University. In addition to his primary position at Temple, Torres-Ayuso will hold a dual appointment in the molecular therapeutics research program at Fox Chase Cancer Center.
Anthony M. Villano was hired as a clinical instructor in the Department of Surgical Oncology at Fox Chase Cancer Center.
Hayan LeeMichael ScottHayan Lee was named an assistant professor in the Cancer Signaling and Epigenetics research program and the Cancer Epigenetics Institute at Fox Chase Cancer Center.
The Mays Cancer Center at UT Health San Antonio and Evestra Inc., a San Antonio-based biopharmaceutical company, have been awarded a five-year, $3.3 million Academic Industry Partnership grant from NIH for the research and development of a drug targeting ovarian cancer, EC359. It is the first grant of this kind awarded to The University of Texas Health Science Center at San Antonio.
The American Cancer Society awarded the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, has received two check donations in the amounts of $480,000, for an institutional research grant, and $65,000, for cancer support grants, from the American Cancer Society.
Michele Coté was named director of the Susan G. Komen Tissue Bank, the world’s only healthy breast tissue bank, at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
More than $2 million was raised for research at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
NYU College of Dentistry has received a gift from the Leukemia & Lymphoma Society to create a pilot program to provide financial support for dental care for U.S. military veterans with blood cancer.
Aimee DeGolyer was named the winner of Astellas Pharma U.S.’s sixth annual C3 (Changing Cancer Care) Prize, a global challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers, and the broader oncology community.
